EU-LIFE points out the increasing lack of opportunities for collaborative research in biomedicine at a European level and highlights how this is endangering long-lasting, positive impact in health research for the benefit of citizens. Based on the analysis on the barriers regarding participation in collaborative health research in Horizon 2020, 6 recommendations aim at contributing to improvement for the upcoming seven-year cycle of Horizon Europe.
“Great discoveries of the past centuries tell us that a short-term vision of impact does not contribute to long-standing, sustainable impact”, says Geneviève Almouzni, Chair of EU-LIFE and Head of the Chromatin Dynamics team at Institut Curie, France. “Addressing unmet medical needs requires a return to a more balanced portfolio of research across the entire research and innovation spectrum. This is the only way to ensure a steady flow of powerful innovations from the bench to bedside."
“The path from discovery to innovation is not linear and includes many feedback loops. Long-lasting innovation requires international research collaborations and without it, we risk losing the scientific foundations of future impact” says Marta Agostinho, EU-LIFE Coordinator.
EU-LIFE, an alliance of 13 life science institutes from across Europe, carries out excellent science resulting in global scientific, economic and social impact. Indeed, in the year 2017, together these institutes were awarded 116 ERC grants, published more than 1,000 papers in tier 10 journals and developed more than 86 patents and 6 spin-outs. They employ and train 7,400 staff and scientists.